Answers are grounded in this paper and cite their sources.
Early cancer diagnosis urgently requires reproducible and minimally invasive approaches for dynamic monitoring. Exosomes are stably present in biological fluids, and they are relatively abundant, making them promising biomarkers for liquid biopsy. Raman spectroscopy, particularly surface-enhanced Raman scattering (SERS), enables the acquisition of global molecular fingerprints of exosomes within complex biofluid backgrounds, thereby providing a feasible strategy for noninvasive detection in urine, saliva, and sweat. Studies conducted under controlled laboratory conditions have demonstrated discriminatory potential. However, substantial challenges remain for clinical translation, including insufficient reproducibility, limited comparability due to variations in biofluids and substrates, inconsistencies in instrumentation and analytical workflows, and the lack of standardized modeling strategies. These issues hinder the extrapolation of high-performance experimental results to real-world clinical settings. In this review, key advances in exosome isolation, SERS substrates, signal acquisition, and chemometric or machine-learning-based data analysis are systematically summarized. The applicability boundaries of these approaches across different biofluids and clinical scenarios are evaluated. The biological interpretability of global spectral fingerprints and the reliability of small-sample modeling are discussed. Finally, potential optimization strategies, including standardized workflows, multimodal data integration, and multicenter validation, are proposed to facilitate the clinical translation of noninvasive SERS-based exosome detection.
No takes yet. Share an insight, caveat, or question.
王佳阳 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: